1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024

EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024

Summary

Huntington’s disease (HD) is a rare, inherited, genetic disorder that causes progressive degeneration of the nerve cells of the brain especially the caudate, the putamen, and the cerebral cortex. As the brain cells die, a person with HD is unable to control movements, recall events, make decisions, and control emotions, and the disorder leads to incapacitation, cognitive and psychiatric disorders, and eventually death. The signs and symptoms of HD mostly appear between the ages 30-40 years, although the onset of disease may occur earlier or later in life. Therefore the disease is mostly of adult onset. The average lifespan of a person after being diagnosed with adult-onset HD is about 15-20 years. When the onset of the disease begins earlier than the age 20 years, the condition is called juvenile HD. Juvenile HD presents somewhat different symptoms and has a faster disease progression.

GlobalData epidemiologists forecast an increase in the diagnosed prevalence of HD over the ten-year forecast period. The number of diagnosed prevalent cases of HD in the 7MM will increase from 57,314 cases in 2014 to 60,743 cases in 2024, with an AGR of 0.60% during the forecast period. For juvenile HD, GlobalData epidemiologists forecast an increase from 1,000 diagnosed prevalent cases in 2014 to 1,013 diagnosed prevalent cases in 2024, in the 7MM, with an AGR of 0.13%.

GlobalData epidemiologists used the available data on HD to the best extent possible to provide the most insightful epidemiological forecast for the diagnosed prevalent cases of HD, diagnosed prevalent cases of juvenile HD, diagnosed prevalent cases of HD by age at onset, and diagnosed prevalent cases of adults with juvenile-onset HD that progressed to adulthood in the 7MM. All sources for the 7MM assessed HD by diagnostic testing, including genetic tests. Additionally, the forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed prevalent cases of HD across the markets.

Scope

- The Huntington’s Disease EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for Huntington’s disease (HD) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of HD and juvenile HD, diagnosed prevalent cases of Huntington's disease by age at onset, and diagnosed prevalent cases of adults with juvenile onset HD that progressed to adulthood, segmented by age and sex.
- The HD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Huntington’s Disease EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global HD market.
- Quantify patient populations in the global HD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for HD therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Complications 10
3.3 Global Trends 11
3.3.1 Diagnosed Prevalence of Huntington's Disease - 7MM 11
3.4 Forecast Methodology 13
3.4.1 Sources Used 16
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods 19
3.5 Epidemiological Forecast of Huntington's Disease (2014-2024) 22
3.5.1 Diagnosed Prevalent Cases 22
3.5.2 Diagnosed Prevalent Cases of Huntington's Disease by Age at Onset 35
3.5.3 Diagnosed Prevalent Cases of Adults with Juvenile Onset Huntington's Disease that Progressed to Adulthood, Ages ?20 Years 36
3.6 Discussion 38
3.6.1 Epidemiological Forecast Insight 38
3.6.2 Limitations of the Analysis 39
3.6.3 Strengths of the Analysis 39
4 Appendix 41
4.1 Bibliography 41
4.2 About the Authors 44
4.2.1 Epidemiologists 44
4.2.2 Reviewers 44
4.2.3 Global Director of Therapy Analysis and Epidemiology 45
4.2.4 Global Head of Healthcare 46
4.3 About GlobalData 47
4.4 About EpiCast 47
4.5 Disclaimer 48

1.1 List of Tables
Table 1: Risk Factors and Complications for Huntington's Disease 10
Table 2: 7MM Estimates for the Diagnosed Prevalence of Huntington's Disease 13
Table 3: 7MM, Sources of Epidemiological Data Used for the Forecast of Huntington's Disease Diagnosed Prevalent Cases 14
Table 4: 7MM, Sources of Epidemiological Data Used for the Forecast of Juvenile Huntington's Disease Diagnosed Prevalent Cases 15
Table 5: 7MM, Sources of Epidemiological Data Used for the Forecast of Huntington's Disease Diagnosed Prevalent Cases by Age at Onset 16
Table 6: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, All Ages, Both Sexes, N, 2014-2024 23
Table 7: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age Group, Both Sexes, N (%), 2014 25
Table 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Huntington's Disease, All Ages, N (%), 2014 27
Table 9: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Both Sexes, N (%), 2014 32
Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age Table 12: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset Huntington's Disease that Progressed to Adulthood, Age ?20 Years, Both Sexes, N, 2014-2024 37

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, All Ages, Both Sexes, N, 2014-2024 23
Figure 2: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age Group, Both Sexes, N, 2014 26
Figure 3: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, by Sex, All Ages, N, 2014 28
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Huntington's Disease (%) by Sex, All Ages, 2014 29
Figure 5: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age Figure 6: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease by Age Group, Both Sexes, N 33
Figure 7: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease by Sex, Age Figure 8: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age at Onset, Both Sexes, N, 2014 36
Figure 9: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset Huntington's Disease that Progressed to Adulthood, Age ?20 Years, Both Sexes, N, 2014 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Epilepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Myasthenia Gravis-Market Insights, Epidemiology and Market Forecast-2023

Myasthenia Gravis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Myasthenia Gravis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


Download Unlimited Documents from Trusted Public Sources

Neurological Disorder Statistics in China

  • November 2016
    32 pages
  • Neurological Di...  

    Stroke  

    Neurology  

  • China  

View report >

Global Mental Health Statistics - Forecast

  • November 2016
    12 pages
  • Mental Health  

  • World  

    Greece  

View report >

Depression Statistics in Canada

  • October 2016
    32 pages
  • Depression  

    Mental Health  

    Neurological Di...  

  • Canada  

    North America  

View report >

Related Market Segments :

Neurological Disorder

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.